<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 4, 2000
NOVAVAX, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-26770 22-2816046
-------- ------- ----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation or organization) File No.) Identification No.)
8320 GUILFORD ROAD, COLUMBIA, MD 21046
-------------------------------- -----
(Address of principal executive offices) (Zip code)
(301) 854-3900
--------------
Registrant's telephone number, including area code
NOT APPLICABLE
(Former name or former address, if changed since last report)
<PAGE> 2
NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
The Fielding Pharmaceutical acquisition was completed on December 19,
2000. See Exhibit 99.1 filed with this Form 8-KA.
ITEM 7. EXHIBITS.
Exhibits.
99.1 Press Release issued December 21, 2000.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NOVAVAX, INC.
Date: December 21, 2000 By:
------------------------------
Dennis W. Genge, Vice President
And Chief Financial Officer/Treasurer
